White Knuckles

February 10th 2025

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Your daily dose of the clinical news you may have missed.

February 4th 2025

FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Related Content

February 10th 2025

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Your daily dose of the clinical news you may have missed.

February 4th 2025